Lenalidomide-Associated ITP | Zendy

Christina I. Herold | Zendy; Cristina Gasparetto | Zendy; Gowthami M. Arepally | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lenalidomide-Associated ITP

Author(s) -

Christina I. Herold,

Cristina Gasparetto,

Gowthami M. Arepally

Publication year - 2011

Publication title -

case reports in hematology

Language(s) - English

Resource type - Journals

eISSN - 2090-6560

pISSN - 2090-6579

DOI - 10.1155/2011/638020

Subject(s) - lenalidomide , medicine , multiple myeloma , thalidomide , thrombocytopenic purpura , immune thrombocytopenia , limiting , myelodysplastic syndromes , immune system , immunology , antibody , bone marrow , mechanical engineering , engineering

Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia. The common toxicities of lenalidomide, including dose-limiting myelosuppression, are well described. However, the immunomodulatory properties of lenalidomide may give rise to unexpected autoimmune complications. Herein, we describe a case of immune thrombocytopenic purpura (ITP) associated with use of lenalidomide.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research